NRX Pharmaceuticals, Inc. Revenue from Contract with Customer, Including Assessed Tax
NRX Pharmaceuticals, Inc. (NRXP) reported Revenue from Contract with Customer, Including Assessed Tax of $1.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-14
- NRX Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $1.10M.
- NRX Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $1.07M.
- NRX Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $1.20M.
- NRX Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $242.00K.
- NRX Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $1.45M.
- NRX Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $0.00.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-14 | $2.17M 10-Q · filed 2026-08-14 | $3.37M derived: sum of 3 quarters · filed 2026-08-14 | $3.61M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-15 | $2.27M derived: sum of 2 quarters · filed 2026-05-15 | $2.51M derived: sum of 3 quarters · filed 2026-05-15 | $2.51M derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.45M derived: sum of 2 quarters · filed 2026-03-23 | $1.45M derived: sum of 3 quarters · filed 2026-03-23 | $1.45M 10-K · filed 2026-03-23 |
| 2025-09-30 | $242.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $242.00K derived: sum of 2 quarters · filed 2025-11-14 | $242.00K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $0.00 10-Q · filed 2025-08-18 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $0.00 10-Q · filed 2025-08-18 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |